Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME 344

Drug Profile

ME 344

Alternative Names: ME-344; NV-344

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer MEI Pharma; Sarah Cannon Research Institute; Spanish National Cancer Research Centre; Tennessee Oncology
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer; Ovarian cancer; Small cell lung cancer
  • No development reported Breast cancer; Solid tumours

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, First-line therapy) in Spain (IV, Infusion)
  • 01 Jun 2019 Updated efficacy data from a phase I trial in Breast cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top